REG - Wellnex Life Limited - Company Update

Wellnex LifeAnnouncement

09/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260209:nRSI2187Sa&default-theme=true

RNS Number : 2187S  Wellnex Life Limited  09 February 2026

 

ASX/AIM Announcement
 
            9 February 2026

 

 

Company Update

 

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company")

Further to the Company's recent market update announcing significant
improvement in H1 EBITDA and gross margin, confirming the turnaround
trajectory remains on track, the Board provides the following update regarding
various financing solutions under consideration.

The Company has received unsolicited preliminary interest from separate
parties regarding the acquisition of Pain Away and other assets. Early-stage
due diligence is underway across both approaches.

Additionally, a syndicate has approached the Company with an indicative
early-stage proposal to provide convertible note funding to expand Pain Away
into Asia and North America, aligned with the Company's strategy of delivering
positive free cash flow, profitability and long-term shareholder value.

 

Financing Evaluation

The Board is actively assessing these opportunities alongside traditional debt
and equity options to secure the optimal capital structure to maximise value
for all shareholders, to settle former director loan repayments due in April
2026 and to drive the turnaround in the business and Pain Away brand.

 

The Company will provide further updates in accordance with its continuous
disclosure obligations under ASX Listing Rules and AIM Regulation. There can
be no certainty that any or all of the potential transactions outlined above
will proceed to completion or as to the terms of any transaction Any potential
transaction will be assessed against applicable regulatory requirements.

 

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)
                            Reach Markets

Ash
Vesali
T: 1300 805 941

Executive
Chairman
E: IR@reachmarkets.com.au (mailto:IR@reachmarkets.com.au)

E: ash.v@wellnexlife.com.au (mailto:ash.v@wellnexlife.com.au)

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

 

James Harris / Richard Johnson
                                     Tel:
+44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint
Broker)
swykeham@oranacorp.com (mailto:swykeham@oranacorp.com)

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker)        Tel: +44 (0)20
3470 0470

David Hignell / Vadim Alexandre

 

To learn more, please visit: https://wellnexlife.com.au/
(https://wellnexlife.com.au/)

The information contained within this announcement is deemed by the Company to
constitute inside information pursuant to article 7 of EU Regulation 596/2014
as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 as amended.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQKLBBQLLXBBB



            Copyright 2019 Regulatory News Service, all rights reserved